This is an open-label, single treatment study. All subjects will receive 6 months of oral
      contraceptive therapy with DR-1021. Study participants will receive physical and
      gynecological exams, including Pap smear. During the study, all participants will be required
      to complete a diary.

Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive

Contraception

The overall study duration for each patient will be approximately 8 months, which includes a
      screening period of approximately 4 weeks; a treatment period of approximately six months
      (six,28-day cycles); and a follow-up visit approximately 4 weeks after completion of study
      drug.

Open-Label Study to Evaluate the Safety and Efficacy of a Low-Dose 28-Day Oral Contraceptive

About this trial

Study ID

Status

Type

Phase

Placebo

Accepting

Trial Timing

What is this trial about?

What are the participation requirements?